Trond Williksen, chief executive officer of global aquaculture genetics, health and specialist nutrition firm Benchmark, purchased a total of 180,000 ordinary shares in the company earlier this week.
The shares were bought on Sept. 2 and 3 for a total value of £82,800 (€92,600/$109,000).
Following the purchase, Williksen's total beneficial interest in the company is 180,000 ordinary shares, representing approximately 0.03 percent of the company's issued share capital.
Benchmark has struggled with profitability in recent years, but managed to half its losses in the third quarter of 2020 as it neared completion of its divestment program.
The group’s overall adjusted loss amounted to £1.5 million (€1.7 million/$2 million) compared with a loss of £3 million (€3.3 million/$4 million) in the same period a year ago.
